Skip to main content
Erschienen in: rheuma plus 2/2015

01.07.2015 | Rheuma bei Kindern

Klinik und Therapie rheumatischer Erkrankungen und Vaskulitiden im Kindesalter

verfasst von: PD Dr. K. Tenbrock

Erschienen in: rheuma plus | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Rheumatische Erkrankungen bei Kindern und Jugendlichen stellen nach dem Diabetes mellitus die zweithäufigste Form von Autoimmunerkrankungen im Kindesalter dar. Wegen kutaner Symptome ist der Dermatologe oft auch der erste Ansprechpartner für diese Kinder und ihre Eltern. Die juvenile idiopathische Arthritis ist die häufigste rheumatische Erkrankung im Kindesalter. Abgesehen von der systemischen Verlaufsform und der Psoriasisarthritis geht diese in der Regel nicht mit Hautsymptomen einher. Im Gegensatz dazu gibt es eine ganze Reihe rheumatischer Erkrankungen, wie z. B. die Purpura Schönlein-Henoch, den systemischen Lupus erythematodes oder das Kawasaki-Syndrom, die sich mit Hauterscheinungen manifestieren. Die Kenntnisse dieser Krankheitsbilder sind daher von großem Wert für den Dermatologen.
Literatur
1.
Zurück zum Zitat Berntson L, Fasth A, Andersson-Gare B et al (2001) Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol 28(12):2737–2743PubMed Berntson L, Fasth A, Andersson-Gare B et al (2001) Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism. J Rheumatol 28(12):2737–2743PubMed
2.
Zurück zum Zitat Minden K, Niewerth M (2008) Juvenile idiopathic arthritis – clinical subgroups and classification. Z Rheumatol 67(2):100, 102–106, 108-110PubMedCrossRef Minden K, Niewerth M (2008) Juvenile idiopathic arthritis – clinical subgroups and classification. Z Rheumatol 67(2):100, 102–106, 108-110PubMedCrossRef
3.
Zurück zum Zitat Woo P, Southwood TR, Prieur AM et al (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43(8):1849–1857PubMedCrossRef Woo P, Southwood TR, Prieur AM et al (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43(8):1849–1857PubMedCrossRef
4.
Zurück zum Zitat Rossum MA van, Soesbergen RM van, Boers M et al (2007) Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 66(11):1518–1524PubMedCentralPubMedCrossRef Rossum MA van, Soesbergen RM van, Boers M et al (2007) Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 66(11):1518–1524PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Silverman E, Mouy R, Spiegel L et al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352(16):1655–1666PubMedCrossRef Silverman E, Mouy R, Spiegel L et al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352(16):1655–1666PubMedCrossRef
6.
Zurück zum Zitat Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820PubMedCrossRef Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820PubMedCrossRef
7.
Zurück zum Zitat Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391PubMedCrossRef Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391PubMedCrossRef
8.
Zurück zum Zitat Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289PubMedCrossRef Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289PubMedCrossRef
9.
Zurück zum Zitat Heiberg MS, Kaufmann C, Rodevand E et al (2007) The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 66(8):1038–1042PubMedCentralPubMedCrossRef Heiberg MS, Kaufmann C, Rodevand E et al (2007) The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 66(8):1038–1042PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Paller AS, Siegfried EC, Langley RG et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358(3):241–251PubMedCrossRef Paller AS, Siegfried EC, Langley RG et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358(3):241–251PubMedCrossRef
11.
Zurück zum Zitat Wittkowski H, Frosch M, Wulffraat N et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58(12):3924–3931PubMedCentralPubMedCrossRef Wittkowski H, Frosch M, Wulffraat N et al (2008) S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 58(12):3924–3931PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Frosch M, Ahlmann M, Vogl T et al (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(3):883–891PubMedCrossRef Frosch M, Ahlmann M, Vogl T et al (2009) The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60(3):883–891PubMedCrossRef
13.
Zurück zum Zitat Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France. Ann Rheum Dis 67(3):302–308PubMedCrossRef Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France. Ann Rheum Dis 67(3):302–308PubMedCrossRef
14.
Zurück zum Zitat Mihara M, Nishimoto N, Ohsugi Y (2005) The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 5(5):683–690PubMedCrossRef Mihara M, Nishimoto N, Ohsugi Y (2005) The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 5(5):683–690PubMedCrossRef
15.
Zurück zum Zitat Newburger JW, Takahashi M, Beiser AS et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324(23):1633–1639PubMedCrossRef Newburger JW, Takahashi M, Beiser AS et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324(23):1633–1639PubMedCrossRef
16.
Zurück zum Zitat Ruperto N, Ravelli A, Pistorio A et al (2008) The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59(1):4–13PubMedCrossRef Ruperto N, Ravelli A, Pistorio A et al (2008) The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 59(1):4–13PubMedCrossRef
17.
Zurück zum Zitat Rouster-Stevens KA, Gursahaney A, Ngai KL et al (2008) Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 59(2):222–226PubMedCentralPubMedCrossRef Rouster-Stevens KA, Gursahaney A, Ngai KL et al (2008) Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 59(2):222–226PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Fisler RE, Liang MG, Fuhlbrigge RC et al (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47(4):505–511PubMedCrossRef Fisler RE, Liang MG, Fuhlbrigge RC et al (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47(4):505–511PubMedCrossRef
19.
Zurück zum Zitat Chiu SK, Yang YH, Wang LC, Chiang BL (2007) Ten-year experience of juvenile dermatomyositis: a retrospective study. J Microbiol Immunol Infect 40(1):68–73PubMed Chiu SK, Yang YH, Wang LC, Chiang BL (2007) Ten-year experience of juvenile dermatomyositis: a retrospective study. J Microbiol Immunol Infect 40(1):68–73PubMed
20.
Zurück zum Zitat Peterson LS, Nelson AM, Su WP et al (1997) The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol 24(1):73–80PubMed Peterson LS, Nelson AM, Su WP et al (1997) The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol 24(1):73–80PubMed
21.
Zurück zum Zitat Zulian F, Athreya BH, Laxer R et al (2006) Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45(5):614–620 Zulian F, Athreya BH, Laxer R et al (2006) Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 45(5):614–620
22.
Zurück zum Zitat Zulian F, Vallongo C, Woo P et al (2005) Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52(9):2873–2881PubMedCrossRef Zulian F, Vallongo C, Woo P et al (2005) Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 52(9):2873–2881PubMedCrossRef
23.
Zurück zum Zitat Uziel Y, Feldman BM, Krafchik BR et al (2000) Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 136(1):91–95PubMedCrossRef Uziel Y, Feldman BM, Krafchik BR et al (2000) Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 136(1):91–95PubMedCrossRef
24.
Zurück zum Zitat Ramirez Gomez LA, Uribe UO, Osio UO et al (2008) Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 17(6):596–604CrossRef Ramirez Gomez LA, Uribe UO, Osio UO et al (2008) Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 17(6):596–604CrossRef
25.
Zurück zum Zitat Baca V, Lavalle C, Garcia R et al (1999) Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 26(2):432–439PubMed Baca V, Lavalle C, Garcia R et al (1999) Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 26(2):432–439PubMed
26.
Zurück zum Zitat Buratti S, Szer IS, Spencer CH et al (2001) Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28(9):2103–2108PubMed Buratti S, Szer IS, Spencer CH et al (2001) Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28(9):2103–2108PubMed
27.
Zurück zum Zitat McCarthy HJ, Tizard EJ (2010) Clinical practice: diagnosis and management of Henoch-Schonlein purpura. Eur J Pediatr 169(6):643–650PubMedCrossRef McCarthy HJ, Tizard EJ (2010) Clinical practice: diagnosis and management of Henoch-Schonlein purpura. Eur J Pediatr 169(6):643–650PubMedCrossRef
Metadaten
Titel
Klinik und Therapie rheumatischer Erkrankungen und Vaskulitiden im Kindesalter
verfasst von
PD Dr. K. Tenbrock
Publikationsdatum
01.07.2015
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 2/2015
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-015-0026-2

Weitere Artikel der Ausgabe 2/2015

rheuma plus 2/2015 Zur Ausgabe

ÖGR-Jahrestagung 2014

Neues von „BioReg“